Project Grant HT9425261E432
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $3.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $2 million under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, to support the Prostate Cancer Clinical Trials Consortium. The award funds clinical trial coordination and research activities from September 30, 2026, through September 29, 2030, at Dana-Farber's Boston, Massachusetts location. The Military Medical Research and Development program supports basic, applied, and advanced...
- The Defense Health Agency awarded The Rockefeller University $1.649998 million on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct therapeutic targeting of a commonly inherited breast cancer metastasis driver gene. Work performance is located in New York, NY with a period of performance through July 31, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...
- The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
- The Defense Health Agency awarded the Beckman Research Institute of the City of Hope $416,217 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop photoacoustic computed tomography technology for identifying and diagnosing axillary lymph nodes in breast cancer patients without surgery. Performance runs through September 29, 2029, at the Institute's Irwindale, California research facility. The Military Medical Research and Development program...
- The Defense Health Agency awarded George Mason University $501,515 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the role of PIK3CA mutations in tumorigenesis of HER2-positive breast cancer. Work is performed in Fairfax, Virginia, with a period of performance through August 31, 2029. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded Yale University $1.05 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on harnessing myeloid cell ontogeny to prevent melanoma brain metastasis. The award funds basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for the battlefield. Performance will occur in New...
- The Defense Health Agency awarded the University of Melbourne $1,121,554 on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel biological therapies targeting a tumor-specific isoform of HER2 for treatment of advanced breast cancer. The award obligates $1,121,554 through March 31, 2029. Work is performed in Australia. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform...
- The Defense Health Agency awarded the University of Pittsburgh $1.8 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate mechanisms and develop innovative therapies for ESR1-CCDC170 fusions in clinically aggressive, endocrine-resistant, and metastatic breast cancers. The award supports a three-year project period ending April 30, 2029, with work performed at the University of Pittsburgh in Pittsburgh, Pennsylvania. The Military...
- The Defense Health Agency awarded the University of California, Los Angeles $3.499992 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to fund a project activating a B cell response against breast cancer. The award obligates $3.499992 million across a three-year period of performance through August 31, 2029, with place of performance in Los Angeles, California. Work is conducted through UCLA's Office of Research Administration, the...